Advertisement

Predictive Toxicogenomics in Preclinical Discovery

  • Scott A. Barros
  • Rory B. Martin
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 460)

Summary

The failure of drug candidates during clinical trials due to toxicity, especially hepatotoxicity, is an important and continuing problem in the pharmaceutical industry.

This chapter explores new predictive toxicogenomics approaches to better understand the hepatotoxic potential of human drug candidates and to assess their toxicity earlier in the drug development process. The underlying data consisted of two commercial knowledgebases that employed a hybrid experimental design in which human drug-toxicity information was extracted from the literature, dichotomized, and merged with rat-based gene expression measures (primary isolated hepatocytes and whole liver). Toxicity classification rules were built using a stochastic gradient boosting machine learner, with classification error estimated using a modified bootstrap estimate of true error. Several types of clustering methods were also applied, based on sets of compounds and genes. Robust classification rules were constructed for both in vitro (hepatocytes) and in vivo (liver) data, based on a high-dose, 24-h design. There appeared to be little overlap between the two classifiers, at least in terms of their gene lists. Robust classifiers could not be fitted when earlier time points and/or low-dose data were included, indicating that experimental design is important for these systems. Our results suggest development of a compound screening assay based on these toxicity classifiers appears feasible, with classifier operating characteristics\break used to tune a screen for a specific implementation within preclinical testing paradigms.

Keywords

classification rule in vitro in vivo machine learning stochastic gradient boosting toxicity toxicogenomics 

Notes

Acknowledgement

The authors thank our colleagues at Millennium Pharmaceuticals, Inc.—Arek Raczynski, Carl Alden, and Scott Coleman—for their scientific input and thoughtful review of this work; and Victor Farutin for his expert help implementing stochastic gradient boosting. We also thank Gene Logic Inc. for supplying the in vivo and in vitro gene expression data. Permission to reproduce material was obtained from Future Medicine for the inclusion of parts of the following papers from Pharmacogenomics:

•Barros, S. (2005) The importance of applying toxicogenomics to increase the efficiency of drug discovery. Pharmacogenomics 6(6), 547–550.

•Martin, R., Rose, D., Yu, K., and Barros, S. (2006) Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7(7), 1003–1016.

•Martin, R. and Yu, K. (2006) Assessing performance of prediction rules in machine learning. Pharmacogenomics 7(4), 543–550.

References

  1. 1.
    Kola, I. and Landis, J. (2004) Can the pharmaceutical industryreduce attrition rates? Nat. Rev. Drug Discov. 3,711–715.CrossRefPubMedGoogle Scholar
  2. 2.
    DiMasi, J., Hansen, R., and Grabowski, H. (2003) The price ofinnovation: new estimates of drug development costs. J. HealthEcon. 22, 151–185.Google Scholar
  3. 3.
    Dambach, D.M., Andrews, B.A., and Moulin, F. (2005) New technologiesand screening strategies for hepatotoxicity: use of in vitromodels. Toxicol. Pathol. 33, 17–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat.Rev. Drug Discov. 4, 489–499.CrossRefPubMedGoogle Scholar
  5. 5.
    Raghavan, N., Amaratunga, D., Nie, A., and McMillian, M. (2004) Class prediction in toxicogenomics. J. Biopharm. Stat. 15, 327–341.CrossRefGoogle Scholar
  6. 6.
    Natsoulis, G., Ghaoui, L., Lanckriet, G., Tolley, A., Leroy, F., Dunlea, S., et al. (2005) Classification of a large microarray dataset: algorithm comparison and analysis of drug signatures. Genome Res. 15, 724–736.CrossRefPubMedGoogle Scholar
  7. 7.
    Breiman, L. (2001) Statistical modeling: the two cultures. Stat. Sci. 16, 199–231.CrossRefGoogle Scholar
  8. 8.
    Efron, B. and Tibshirani, R. (1997) Improvements oncross-validation: the .632+ bootstrap method. JASA 92,548–560.Google Scholar
  9. 9.
    Hastie, T., Tibshirani, R., and Friedman, J. (2001) TheElements of Statistical Learning. Springer-Verlag, New York.Google Scholar
  10. 10.
    Efron, B. (1983): Estimating the error rate of a prediction rule. JASA 78, 316–331.Google Scholar
  11. 11.
    Martin, R. and Yu, K. (2006) Assessing performance of predictionrules in maching learning. Pharmacogenomics 7(4), 543–550.CrossRefPubMedGoogle Scholar
  12. 12.
    Fields, R.D. and Lancaster, M.V. (1993) Dual-attribute continuousmonitoring of cells proliferation/cytotoxicity. Am. Biotechnol.Lab. 11, 48–50.PubMedGoogle Scholar
  13. 13.
    Affymetrix RGU34A microarray. Available at www.affymetrix.com/analysis/index.affx.
  14. 14.
    Irizarry, R., Hobbs, B., Colin, F., Beazer-Barclay, Y., Antonellis,K., Scherf, U., and Speed, T. (2003) Exploration, normalization, andsummaries of high density oligonucleotide array probe level data. Biostatistics 2, 249–264.CrossRefGoogle Scholar
  15. 15.
    Friedman, J. (1996). Greedy function approximation: a gradientboosting machine. Ann. Stat. 29, 1189–1232.CrossRefGoogle Scholar
  16. 16.
    Luenberger, D. (2003) Linear and Nonlinear Programming, 2nded. Springer, Berlin.Google Scholar
  17. 17.
    Metrigenix. Corporate home page. Available at www.metrigenix.com.
  18. 18.
    Brieman, L., Friedman, J., Olshen, R., and Stone, C. (1998) Classification and Regression Tree. Chapman and Hall/CRC, BocaRaton, FL.Google Scholar
  19. 19.
    Therneau, T. and Atkinson, E. (1997) An introduction to recursivepartitioning using the rpart routines. Mayo Clinic TechnicalReport.Google Scholar
  20. 20.
    Baker, T., Carfagna, M., Gao, H., Dow, E., Li, Q., Searfoss, G., and Ryan, T. (2001) Temporal gene expression analysis of monolayercultured rat hepatocytes. Chem. Res. Toxicol. 14, 1218–1231.CrossRefPubMedGoogle Scholar
  21. 21.
    Morghe, P., Berthiaume, F., Ezzell, R., Toner, M., Tompkins, R., and Yarmush, M. (1996) Culture matrix configuration and composition inthe maintenance of hepatocyte polarity and function. Biomaterials 17, 373–385.CrossRefGoogle Scholar
  22. 22.
    Farkas, D. and Tannenbaum, S. (2005) In vitro methods to studychemically-induced hepatotoxicity: a literature review. Curr.Drug Metab. 6, 111–125.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Scott A. Barros
    • 1
  • Rory B. Martin
    • 2
  1. 1.ToxicologyArchemix Corp.Cambridge
  2. 2.Drug Safety and DispositionMillennium

Personalised recommendations